Primary (prespecified interim) analysis

Primary endpoint: IDFS1§

42%

REDUCTION IN RISK OF INVASIVE DISEASE RECURRENCE, NEW CANCERS, OR DEATH VS PLACEBO

HR=0.58 (95% CI: 0.46–0.74); P<0.0001

See the IDFS data

Primary (prespecified interim) analysis

Key secondary endpoint: OS1

32%

REDUCTION IN RISK OF DEATH VS PLACEBO

HR=0.68 (95% CI: 0.50–0.91); P=0.0091

See the OS data

Not an actual patient.

Explore OlympiA follow-up data at 6 years

See the safety data for OlympiA

Exploratory analysis from the OlympiA trial

OlympiA Trial 6 Year Data

NEW Publication

See the publication for a 6-year exploratory analysisII from the OlympiA trial.2

View the NEW Publication

LYNPARZA eBC Data Brochure

A resource with data summaries from the OlympiA clinical trial, including exploratory 6-year follow-up data.

Download Brochure

LYNPARZA for the treatment of certain patients with gBRCAm,† HER2-negative metastatic breast cancer1

The OlympiAD trial evaluated progression-free survival, objective response rate, and overall survival.1

Explore OlympiAD efficacy data

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Olaparib (LYNPARZA) is the only PARPi recommended as an NCCN Category 1II preferred regimen in both the adjuvant and metastatic breast cancer settings in eligible patients2

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

IICategory 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

~1 in 10 patients with HER2-negative BC has a gBRCA mutation3-9

Understand more about patients with a gBRCA mutation, regardless of HR status

1 in 10 Patients with HER2-negative BC has a gBRCA Mutation 1 in 10 Patients with HER2-negative BC has a gBRCA Mutation
Testing for gBRCAm
  • *Treatment was continued for up to 1 year, or until disease recurrence, or unacceptable toxicity.1
  • †Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.1
  • ‡For patients who received prior neoadjuvant chemotherapy, high risk was defined as non-pCR in TNBC and as non-pCR with CPS&EG score ≥3 in HR-positive, HER2-negative disease. For patients who received prior adjuvant chemotherapy, high risk was defined as ≥pN1 or pN0 with ≥pT2 in TNBC and as ≥4 positive lymph nodes in HR-positive, HER2-negative disease.1
  • §IDFS was defined as time to first invasive breast cancer recurrence (loco-regional or distant), second primary cancer, or death from any cause.1

IQVIA LAAD (Longitudinal Access and Adjudication Dataset) prescription claims data, National Prescription Audit as of April 2025. #1 for new prescriptions and for total prescriptions.